{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:35:57Z","timestamp":1787060157390,"version":"build-2736575974"},"reference-count":88,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T00:00:00Z","timestamp":1710633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Chronic hepatitis B (CHB) is a global health challenge that can result in significant liver-related morbidity and mortality. Despite a prophylactic vaccine being available, patients already living with CHB often must engage in lifelong therapy with nucleoside analogues. However, the potential of RNA interference (RNAi) therapeutics as a promising avenue for CHB treatment is being explored. RNAi, particularly using small interfering RNA (siRNA), targets viral RNA that can be used to inhibit hepatitis B virus (HBV) replication. Several candidates are currently being studied and have exhibited varying success in reducing hepatitis B surface antigen (HBsAg) levels, with some showing sustained HBsAg loss after cessation of therapy. The dynamic evolution of RNAi therapy presents a promising trajectory for the development of effective and sustained treatments for CHB. This review highlights recent findings on RNAi therapeutics, including modifications for stability, various delivery vectors, and specific candidates currently in development.<\/jats:p>","DOI":"10.3390\/microorganisms12030599","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T06:58:39Z","timestamp":1710745119000},"page":"599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects"],"prefix":"10.3390","volume":"12","author":[{"given":"Laura","family":"Sneller","sequence":"first","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie","family":"Price","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7471-0812","authenticated-orcid":false,"given":"Shyam","family":"Kottilil","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-4672","authenticated-orcid":false,"given":"Joel V.","family":"Chua","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,17]]},"reference":[{"key":"ref_1","unstructured":"Harris, A. (2023). Hepatitis B, Centers for Disease Control and Prevention."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors Associated with Rates of HBsAg Seroclearance in Adults with Chronic HBV Infection: A Systematic Review and Meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/hep.22881","article-title":"Hepatitis B: The virus and disease","volume":"49","author":"Liang","year":"2009","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/liv.14298","article-title":"Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a","volume":"40","author":"Rinker","year":"2020","journal-title":"Liver Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jceh.2016.07.002","article-title":"Clinical Significance of Quantitative HBsAg Titres and its Correlation with HBV DNA Levels in the Natural History of Hepatitis B Virus Infection","volume":"6","author":"Karra","year":"2021","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2051","DOI":"10.1002\/rmv.2051","article-title":"Pregenomic RNA: How to assist the management of chronic hepatitis B?","volume":"29","author":"Wu","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mak, L.-Y., Seto, W.-K., and Yuen, M.-F. (2021). Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. Viruses, 13.","DOI":"10.3390\/v13061169"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular Mechanisms and Biological Functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int. J. Biomed. Sci. IJBS"},{"key":"ref_11","unstructured":"Han, H. (2018). Disease Gene Identification: Methods and Protocols, Springer."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients with Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"van den Berg, F., Limani, S.W., Mnyandu, N., Maepa, M.B., Ely, A., and Arbuthnot, P. (2020). Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses, 12.","DOI":"10.3390\/v12080851"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1053\/j.gastro.2005.01.017","article-title":"Therapies for hepatitis B: Where to from here?","volume":"128","author":"Locarnini","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3893","article-title":"Identification of liver-specific enhancer\u2013promoter activity in the 3\u2032 untranslated region of the wild-type AAV2 genome","volume":"49","author":"Logan","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: Global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/j.gastro.2004.12.007","article-title":"RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant","volume":"128","author":"Wu","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17589","DOI":"10.3390\/ijms160817589","article-title":"Progress and Prospects of Anti-HBV Gene Therapy Development","volume":"16","author":"Maepa","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/oli.2008.0149","article-title":"Stability Study of Unmodified siRNA and Relevance to Clinical Use","volume":"18","author":"Hickerson","year":"2008","journal-title":"Oligonucleotides"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/nar\/gkg393","article-title":"Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells","volume":"31","author":"Czauderna","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/hep.20702","article-title":"Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication","volume":"41","author":"Morrissey","year":"2005","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1122","article-title":"Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs","volume":"23","author":"Morrissey","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4161\/adna.1.1.11981","article-title":"Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs","volume":"1","author":"Hean","year":"2010","journal-title":"Artif. DNA PNA XNA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2015.04.042","article-title":"Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs","volume":"209","author":"Marimani","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejphar.2013.09.050","article-title":"5\u2032-Triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells","volume":"721","author":"Chen","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1021\/bi500602z","article-title":"Structure-Based Design of Novel Chemical Modification of the 3\u2032-Overhang for Optimization of Short Interfering RNA Performance","volume":"54","author":"Xu","year":"2015","journal-title":"Biochemistry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/cbic.201402551","article-title":"Base Modification Strategies to Modulate Immune Stimulation by an siRNA","volume":"16","author":"Valenzuela","year":"2015","journal-title":"ChemBioChem"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/JVI.80.1.426-439.2006","article-title":"Liver Transduction with Recombinant Adeno-Associated Virus Is Primarily Restricted by Capsid Serotype Not Vector Genotype","volume":"80","author":"Grimm","year":"2006","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101705","DOI":"10.1016\/j.cocis.2023.101705","article-title":"Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery","volume":"66","author":"Campbell","year":"2023","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1021\/mp800157x","article-title":"Controlling HBV Replication in Vivo by Intravenous Administration of Triggered PEGylated siRNA-Nanoparticles","volume":"6","author":"Carmona","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.celrep.2015.07.019","article-title":"In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector","volume":"12","author":"Zinn","year":"2015","journal-title":"Cell Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/hum.2018.007","article-title":"Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions","volume":"29","author":"Kassner","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1021\/jm049481d","article-title":"Design and Synthesis of Novel N -Acetylgalactosamine-Terminated Glycolipids for Targeting of Lipoproteins to the Hepatic Asialoglycoprotein Receptor","volume":"47","author":"Rensen","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/hep4.1933","article-title":"Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing","volume":"6","author":"Zhou","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.1093\/nar\/gkx818","article-title":"Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc\u2013siRNA conjugates","volume":"45","author":"Nair","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1128\/AAC.00067-08","article-title":"Long-Term Suppression of Hepatitis B Virus Replication by Short Hairpin RNA Expression Using the Scaffold\/Matrix Attachment Region-Based Replicating Vector System pEPI-1","volume":"52","author":"Jenke","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2008.04.001","article-title":"Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts","volume":"80","author":"Snyder","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_40","unstructured":"Warnock, J.N., Daigre, C., and Al-Rubeai, M. (2011). Viral Vectors for Gene Therapy: Methods and Protocols, Springer."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.omtn.2017.04.007","article-title":"Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs","volume":"7","author":"Maepa","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/gt.2014.94","article-title":"Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses","volume":"22","author":"Ivacik","year":"2015","journal-title":"Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1073\/pnas.0409028102","article-title":"Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs","volume":"102","author":"Uprichard","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2005.10.013","article-title":"Effective Inhibition of HBV Replication in Vivo by Anti-HBx Short Hairpin RNAs","volume":"13","author":"Carmona","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: From concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Deng, L., Li, G., Xi, L., Yin, A., Gao, Y., You, W., Wang, X., and Sun, B. (2009). Hepatitis B virus inhibition in mice by lentiviral vector mediated short hairpin RNA. BMC Gastroenterol., 9.","DOI":"10.1186\/1471-230X-9-73"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3350\/kjhep.2009.15.1.15","article-title":"Inhibition of in vitro hepatitis B virus replication by lentivirus-mediated short-hairpin RNA against HBx","volume":"15","author":"Kim","year":"2009","journal-title":"Korean J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Munis, A.M. (2020). Gene Therapy Applications of Non-Human Lentiviral Vectors. Viruses, 12.","DOI":"10.3390\/v12101106"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Mowa, M.B., Crowther, C., Ely, A., and Arbuthnot, P. (2014). Inhibition of Hepatitis B Virus Replication by Helper Dependent Adenoviral Vectors Expressing Artificial Anti-HBV Pri-miRs from a Liver-Specific Promoter. BioMed Res. Int., 2014.","DOI":"10.1155\/2014\/718743"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.gt.3302846","article-title":"Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin, R.N.A","volume":"14","author":"Chen","year":"2007","journal-title":"Gene Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.15252\/emmm.201506172","article-title":"Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA","volume":"8","author":"Michler","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"105366","DOI":"10.1016\/j.antiviral.2022.105366","article-title":"Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs","volume":"204","author":"Mao","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/mt.2008.245","article-title":"Comparative Study of Anti-hepatitis B Virus RNA Interference by Double-stranded Adeno-associated Virus Serotypes 7, 8, and 9","volume":"17","author":"Chen","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/gt.2015.74","article-title":"AAV ancestral reconstruction library enables selection of broadly infectious viral variants","volume":"22","author":"Ojala","year":"2015","journal-title":"Gene Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gutjnl-2020-323445","article-title":"Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment","volume":"71","author":"Yuen","year":"2022","journal-title":"Gut"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients with Chronic Hepatitis B Infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cpdd.318","article-title":"Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers","volume":"6","author":"Schluep","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_59","unstructured":"Arbutus Biopharma Corporation (2023, December 13). Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives. 7 March 2019. Available online: https:\/\/investor.arbutusbio.com\/news-releases\/news-release-details\/arbutus-reports-fourth-quarter-and-year-end-2018-financial."},{"key":"ref_60","unstructured":"Agarwal, K., Gane, E., Cheng, W., Sievert, W., Roberts, S., Ahn, S.H., Kim, Y.J., Streinu-Cercel, A., Denning, J., and Symonds, W. (2017, January 20\u201324). Bi-weekly Dosing of ARB-1467 LNP siRNA in HBeAgNegative, Virally Suppressed Patients with Chronic HBV Infection Leads to Deeper Declines in HBsAg and Potential Association with IL28b. Proceedings of the American Association for the Study of Liver Diseases\u2019 Liver Meeting, Washington, DC, USA."},{"key":"ref_61","first-page":"62A","article-title":"Safety and pharmacodynamics of the GALNAC-siRNA AB-729 in subjects with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"ref_62","first-page":"S761","article-title":"Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers","volume":"75","author":"Paratala","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_63","first-page":"S760","article-title":"Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms, H.B.V.R.N.A","volume":"75","author":"Thi","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_64","unstructured":"Yuen, M., Berliba, E., Sukeepaisarnjaroen, W., Tangkijvanich, P., Leerapun, A., Holmes, J., Gane, E., Jucov, A., Thi, E., and Sofia, M. (2021, January 13\u201315). Low HBsAg Levels Maintained following Cessation of the Galnac-Sirna, Ab-729, in Chronic Hepatitis B Subjects on Nucleos(T)Ide Analogue Therapy. Proceedings of the American Association for the Study of Liver Diseases\u2019 Liver Meeting, Digital."},{"key":"ref_65","unstructured":"Lim, T.H., Yoon, J.-H., Schwabe, C., Thompson, A., Brown, B., and Gane, E. (2020, January 13\u201316). LO9\u2014HBV RNAi Inhibitor RG6346 in Phase 1b-2a TRIAL Was Safe, Well-Tolerated, and Resulted in Substantial and Durable Reductions in Serum HBsAg Levels. Proceedings of the American Association for the Study of Liver Diseases\u2019 Liver Meeting, Digital."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1093\/nar\/gkac539","article-title":"From bench to bedside: Improving the clinical safety of GalNAc\u2013siRNA conjugates using seed-pairing destabilization","volume":"50","author":"Schlegel","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40268-021-00369-w","article-title":"Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection","volume":"21","author":"Gupta","year":"2021","journal-title":"Drugs R&D"},{"key":"ref_70","first-page":"S287","article-title":"Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: Week 48 follow-up results","volume":"75","author":"Gane","year":"2021","journal-title":"Hepatology"},{"key":"ref_71","unstructured":"Yuen, M.-F., Locarnini, S., Given, B., Schluep, T., Hamilton, J., Biermer, M., Kalmeijer, R., Beumont, M., Lenz, O., and Cloherty, G. (2019, January 8\u201312). First Clinical Experience with RNA Interference-based Triple Combination Therapy in Chronic Hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos(t)ide Analogue. Proceedings of the American Association for the Study of Liver Diseases\u2019 Liver Meeting, Boston, MA, USA."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","article-title":"Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): A multicentre, double-blind, active-controlled, randomised, phase 2b trial","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNAJNJ-3989 induce rapid sometimes prolonged viral responses in patients with, C.H.B","volume":"77","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S1162","DOI":"10.1016\/S0168-8278(23)03303-2","article-title":"Safety pharmacokinetics antiviral activity of single ascending doses of, A.L.G.-1.2.5.7.5.5.; a GalNAc-conjugated small interfering, R.N.A.; in subjects with chronic hepatitis, B","volume":"78","author":"Jucov","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_75","unstructured":"Hong, J., Montero, S.M., Tan, H., de Costa, T., Nie, Y., Pandey, R., Rajwanshi, V., Bhattacharya, A., Kao, C., and Kang, H. (2017, January 20\u201324). ALG-125755, a Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model. Proceedings of the American Association for the Study of Liver Diseases\u2019 Liver Meeting, Washington, DC, USA."},{"key":"ref_76","first-page":"1091A","article-title":"ALN-HBV, a GalNAc-siRNA Enhanced Stabilization Chemistry RNAi Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection: 1857","volume":"60","author":"Abrams","year":"2014","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S0618-8278(19)30092-1","article-title":"PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU\/mL threshold","volume":"70","author":"Yuen","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_78","unstructured":"Yuen, R., Lim, Y.-S., Cloutier, D., Thanawala, V., Shen, L., Arizpe, A., Tay, C., Gupta, S.V., Cathcart, A., and Hwang, C. (2021, January 13\u201315). Preliminary results from a phase 2 study evaluating vir-2218 alone and in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection. Proceedings of the American Association for the Study of Liver Diseases\u2019 Liver Meeting, Digital Experience, Online."},{"key":"ref_79","unstructured":"Hoffmann-La Roche (2020). A Trial to Evaluate the Efficacy and Safety of Multiple Combination Therapies in Participants with Chronic Hepatitis B (Piranga), Hoffmann-La Roche. NCT04225715."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e00082-18","DOI":"10.1128\/AAC.00082-18","article-title":"Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation","volume":"62","author":"Mani","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.3748\/wjg.v13.i16.2324","article-title":"Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells","volume":"13","author":"Li","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbrc.2003.10.009","article-title":"Inhibition of hepatitis B virus replication by stably expressed, s.h.R.N.A","volume":"311","author":"Chen","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1631\/jzus.2005.B0236","article-title":"Combination of small interfering RNAs mediates greater inhibition of human hepatitis B virus replication and antigen expression","volume":"6B","author":"Chen","year":"2005","journal-title":"J. Zhejiang Univ. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wooddell, C.I., Gehring, A.J., Yuen, M.-F., and Given, B.D. (2021). RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. Viruses, 13.","DOI":"10.3390\/v13040581"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Bunse, T., Kosinska, A.D., Michler, T., and Protzer, U. (2022). PD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis, B. Biomolecules, 12.","DOI":"10.3390\/biom12030470"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: A phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat. Med."},{"key":"ref_87","first-page":"S720","article-title":"Combination drug interactions of hepatitis B virus (HBV) small interfering RNA (siRNA) and antisense oligonucleotides (ASO) in vitro and in vivo","volume":"75","author":"Tan","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/3\/599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:14:53Z","timestamp":1760105693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/3\/599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,17]]},"references-count":88,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["microorganisms12030599"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms12030599","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,17]]}}}